Does an Autoimmune Disorder Following Ovarian Cancer Diagnosis Affect Prognosis?

Anaïs Fröhlich, JoEllen Welter, Isabell Witzel, Julia Voppichler, Mathias K Fehr

Abstract read

In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anaïs FröhlichDepartment of Obstetrics and Gynecology, Spital Thurgau AG, 8501 Frauenfeld, Switzerland.ORCID 0009-0006-2021-3208

JoEllen WelterDepartment of Obstetrics and Gynecology, Spital Thurgau AG, 8501 Frauenfeld, Switzerland.

Isabell WitzelDepartment of Gynecology, University Hospital Zürich, University of Zurich, 8091 Zurich, Switzerland.

Julia VoppichlerDepartment of Obstetrics and Gynecology, Spital Thurgau AG, 8501 Frauenfeld, Switzerland.ORCID 0009-0006-7902-6300

Mathias K FehrDepartment of Obstetrics and Gynecology, Spital Thurgau AG, 8501 Frauenfeld, Switzerland.ORCID 0009-0005-2167-3508

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated whether developing an autoimmune disorder (AID) following a high-grade epithelial ovarian cancer diagnosis improves overall survival. This retrospective study included data from women treated for high-grade serous, endometrioid, or transitional cell ovarian, fallopian tube, or peritoneal cancer FIGO stage III or IV at a Swiss cantonal gynecological cancer center (2008-2023). We used Kaplan-Meier estimates and the Cox proportional hazards model using time-varying covariates for the survival function estimation. In all, 9 of 128 patients developed an AID following a cancer diagnosis. The median time from cancer diagnosis to AID was 2 years (IQR 2-5). These women survived for a median of 3031 days (IQR 1765-3963) versus 972 days (IQR 568-1819) for those who did not develop an AID (

Indexed as

Autoimmune DiseasesOvarian NeoplasmsAgedCarcinoma, Ovarian EpithelialFemaleHumansMiddle AgedPrognosisRetrospective Studiesautoimmune diseaseautoimmune disorderovarian canceroverall survivalprognosis

Identifiers

PMID39195327

DOI10.3390/curroncol31080344

PMCPMC11353087

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.